Javier Bustamante

3.1k total citations · 1 hit paper
29 papers, 2.2k citations indexed

About

Javier Bustamante is a scholar working on Hepatology, Surgery and Epidemiology. According to data from OpenAlex, Javier Bustamante has authored 29 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hepatology, 17 papers in Surgery and 9 papers in Epidemiology. Recurrent topics in Javier Bustamante's work include Liver Disease and Transplantation (15 papers), Organ Transplantation Techniques and Outcomes (15 papers) and Renal Transplantation Outcomes and Treatments (9 papers). Javier Bustamante is often cited by papers focused on Liver Disease and Transplantation (15 papers), Organ Transplantation Techniques and Outcomes (15 papers) and Renal Transplantation Outcomes and Treatments (9 papers). Javier Bustamante collaborates with scholars based in Spain, United States and France. Javier Bustamante's co-authors include Joan Rodés, Jordi Bruix, Antoni Castells, R. Vilana, Concepció Brú, Josep M. Llovet, María Sala, Maria Del Carmen Ayuso, Isabel Cirera and Antoni Rimola and has published in prestigious journals such as Hepatology, Journal of Hepatology and Transplantation.

In The Last Decade

Javier Bustamante

28 papers receiving 2.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials

1999 979 citations Javier Bustamante, María Sala et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Javier Bustamante Spain	16	1.8k	1.1k	859	244	237	29	2.2k
Maria Hoppe‐Lotichius Germany	23	1.0k 0.6×	536 0.5×	941 1.1×	166 0.7×	464 2.0×	64	1.8k
Taketoshi Suehiro Japan	28	1.3k 0.7×	555 0.5×	1.4k 1.6×	181 0.7×	244 1.0×	115	2.1k
Alighieri Mazziotti Italy	26	2.2k 1.3×	1.4k 1.3×	1.2k 1.4×	200 0.8×	438 1.8×	77	2.8k
Massimo Malagó Germany	21	751 0.4×	635 0.6×	665 0.8×	276 1.1×	434 1.8×	36	1.7k
Gil‐Chun Park South Korea	23	1.3k 0.7×	536 0.5×	1.4k 1.7×	157 0.6×	404 1.7×	201	2.1k
Mizuki Ninomiya Japan	28	1.4k 0.8×	645 0.6×	1.5k 1.7×	117 0.5×	428 1.8×	91	2.2k
Katharina Staufer Austria	24	966 0.5×	1.0k 1.0×	329 0.4×	269 1.1×	253 1.1×	56	1.9k
Marco Vivarelli Italy	21	752 0.4×	587 0.5×	964 1.1×	188 0.8×	363 1.5×	62	1.7k
Shohei Yoshiya Japan	20	619 0.4×	377 0.3×	580 0.7×	169 0.7×	423 1.8×	94	1.4k
Paolo De Paolis Italy	12	523 0.3×	1.1k 1.0×	455 0.5×	190 0.8×	225 0.9×	53	1.6k

Countries citing papers authored by Javier Bustamante

Since Specialization

Citations

This map shows the geographic impact of Javier Bustamante's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Bustamante with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Bustamante more than expected).

Fields of papers citing papers by Javier Bustamante

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Bustamante. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Bustamante. The network helps show where Javier Bustamante may publish in the future.

Co-authorship network of co-authors of Javier Bustamante

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Bustamante. A scholar is included among the top collaborators of Javier Bustamante based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Bustamante. Javier Bustamante is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gastaca, Mikel, P. Ruíz, Javier Bustamante, et al.. (2021). Early tacrolimus exposure does not impact long-term outcomes after liver transplantation. World Journal of Hepatology. 13(3). 362–374. 3 indexed citations

Prieto, Mikel, Mikel Gastaca, P. Ruíz, et al.. (2020). A case of COVID-19 immediately after liver transplantation: Not only bad news. Annals of Hepato-Biliary-Pancreatic Surgery. 24(3). 314–318. 5 indexed citations

Ruíz, P., Mikel Gastaca, Javier Bustamante, et al.. (2018). Favorable Outcomes After Liver Transplantation With Normothermic Regional Perfusion From Donors After Circulatory Death: A Single-center Experience. Transplantation. 103(5). 938–943. 47 indexed citations

Gastaca, Mikel, Itxarone Bilbao, Javier Bustamante, et al.. (2016). Safety and Efficacy of Early Everolimus When Calcineurin Inhibitors Are Not Recommended in Orthotopic Liver Transplantation. Transplantation Proceedings. 48(7). 2506–2509. 5 indexed citations

Gastaca, Mikel, Andrés Valdivieso, Javier Bustamante, et al.. (2016). Favorable longterm outcomes of liver transplant recipients treated de novo with once‐daily tacrolimus: Results of a single‐center cohort. Liver Transplantation. 22(10). 1391–1400. 14 indexed citations

Turnés, Juan, Roberto Díaz‐Peña, Manuel Hernández‐Guerra, et al.. (2015). Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España. Gastroenterología y Hepatología. 38(4). 263–273. 4 indexed citations

Lladó, Laura & Javier Bustamante. (2013). IV Reunión de Consenso de la Sociedad Española de Trasplante Hepático 2012. Excepciones al Model for End-stage Liver Disease en la priorización para trasplante hepático. Gastroenterología y Hepatología. 37(2). 83–91. 7 indexed citations

Gastaca, Mikel, Francisco A. Miralles‐Muñoz, Andrés Valdivieso, et al.. (2012). Biliary Complications in Orthotopic Liver Transplantation Using Choledochocholedochostomy with a T-tube. Transplantation Proceedings. 44(6). 1554–1556. 19 indexed citations

Valdivieso, Andrés, A. Ventoso, Mikel Gastaca, et al.. (2012). Does the Transjugular Intrahepatic Portosystemic Influence the Outcome of Liver Transplantation?. Transplantation Proceedings. 44(6). 1505–1507. 6 indexed citations

10.

Gómez-Martín, Carlos, Javier Bustamante, J.F. Castroagudı́n, et al.. (2011). Efficacy and Safety of Sorafenib in Combination With Mammalian Target of Rapamycin Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation. Liver Transplantation. 18(1). 45–52. 130 indexed citations

11.

Embade, Nieves, David Fernández‐Ramos, Marta Varela‐Rey, et al.. (2011). Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology. 55(4). 1237–1248. 99 indexed citations

12.

Urbina, J. Ortiz de, Andrés Valdivieso, Mikel Gastaca, et al.. (2011). Advagraf De Novo in Liver Transplantation: A Single-Center Experience. Transplantation Proceedings. 43(3). 724–725. 6 indexed citations

13.

Martínez-López, Nuria, Marta Varela‐Rey, David Fernández‐Ramos, et al.. (2010). Activation of LKB1-Akt Pathway Independent of Phosphoinositide 3-Kinase Plays a Critical Role in the Proliferation of Hepatocellular Carcinoma From Nonalcoholic Steatohepatitis. Hepatology. 52(5). 1621–1631. 59 indexed citations

14.

Valdivieso, Andrés, Javier Bustamante, Mikel Gastaca, et al.. (2010). Management of Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation Proceedings. 42(2). 660–662. 85 indexed citations

15.

Testillano, Milagros, J.R. Fernández, María J. Suárez, et al.. (2009). Survival and Hepatitis C Virus Recurrence After Liver Transplantation in HIV- and Hepatitis C Virus–Coinfected Patients: Experience in a Single Center. Transplantation Proceedings. 41(3). 1041–1043. 13 indexed citations

16.

Varela, Marı́a, María Reig, Manuel de la Mata, et al.. (2009). Tratamiento del carcinoma hepatocelular en España. Análisis de 705 casos en 62 centros. Medicina Clínica. 134(13). 569–576. 39 indexed citations

17.

Montejo, Miguel, Mikel Gastaca, Andrés Valdivieso, et al.. (2009). Prophylactic Therapy With Valgancyclovir in High-Risk (Cytomegalovirus D+/R−) Liver Transplant Recipients: A Single-Center Experience. Transplantation Proceedings. 41(6). 2189–2191. 18 indexed citations

18.

Molina, M. González, R. Marcén, Josep M. Campistol, et al.. (2007). Renal Function in Patients With Cadaveric Kidney Transplants Treated With Tacrolimus or Cyclosporine. Transplantation Proceedings. 39(7). 2167–2169. 6 indexed citations

19.

Bustamante, Javier, Antoni Rimola, Miquel Navasa, et al.. (1999). Prognostic significance of hepatic encephalopathy in patients with cirrhosis. Journal of Hepatology. 30(5). 890–895. 419 indexed citations

20.

Navasa, Miquel, Javier Bustamante, Cláudio Augusto Marroni, et al.. (1996). Diabetes mellitus after liver transplantation: prevalence and predictive factors. Journal of Hepatology. 25(1). 64–71. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact